BionTech – Pharmacy Times | Practical Information for Today’s Pharmacists
A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.
Rucaparib is an oral, small molecule inhibitor being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers.
Pharmacy Times®interviewed Emily Cook, JD, a partner with McDermott Will & Emery, on the final 340B dispute resolution rule, which was recently sent by the HHS to the OMB for review.
The action allows for medicinal products to be authorized on a conditional basis for seriously debilitating or life-threatening diseases or for use in emergency situations in response to public health threats in the European Union.
Evidence suggests that they are not actively using their prescriptive authority, but a new study aims to identify factors affecting their related behaviors.
Based on the pickup rates in the study, the investigators said kiosks could provide pharmacies significant annual savings because patients picked up an additional 400 prescriptions per year.
During a discussion on the adoption of SYK inhibitors as treatment for immune thrombocytopenia, expert panelists remark on the benefits of using the newer oral class of drugs, especially during the COVID-19 pandemic.
Three monoclonal antibodies, 1 antibody-drug conjugate, and 1 nuclear export inhibitor have been approved by the FDA for relapsed/refractory (R/R) multiple myeloma in the past 4 years.
High blood pressure reduces heart function and worsens comorbidities such as diabetes, kidney disease, and vascular disorders.
The ACIP advises the CDC on the populations and circumstances for which vaccines should be used.
Moderna’s COVID-19 vaccine (mRNA-1273) has been granted Emergency Use Authorization (EUA) by the FDA, making it the second vaccine to be issued an EUA for combating the virus.